艾托格列净联合西格列汀治疗肥胖型2型糖尿病患者的疗效及对内脏脂肪面积的影响

打开文本图片集

[中图分类号]R587 [文献标识码]A [文章编号]1672-4062（2026）02（b）-0072-04

The Efficacy of Etogliflozin Combined with Sitagliptin in the Treatment of Obese Patients with Type 2 Diabetes Mellitus and Its Influence on Visceral Fat Area

YANGQichao，YINYong，XUEYi，SHAOXuejing，QIAOHuibo

DepartmentofEndocrinology，WujinHospitalAfiliated toJiangsu University，Changzhou 213Ol7，Jiangsu，China [Abstract]Objective Toinvestigatetheeficacyofetogliflozincombinedwith sitagliptin inthetreatmentof obese type 2 diabetes mellitusand its effcton visceral fat area.Methods A total of 86 patients with obese type 2 diabetes mellitus admited to Wujin Hospital Afiliatedto Jiangsu University from June2024to June2025were selected and dividedintocontrolgroup（43cases，treatedwithsitagliptin）andobservationgroup（43cases，combinedwithetogliflozin）according todiferenttreatment methods.Thebloodglucose metabolism，insulinresistance，bodyfatandother related indicators and adverse reactions were compared between the two groups.Results After treatment， compared with the control group，the levels of -hour postprandial blood glucose，fasting blood glucose and glycated hemoglobin Alc in the observation group were lower than those in thecontrol group，and the body weight，body fat related indexes andinsulinresistance indexes werebetterthanthose in thecontrol group，the differences were statisticallysignificant （all P<0.05 ）.There was no significant diffrence in the incidence of adverse reactions between the two groups （ P> 0.05）.Conclusion Etogliflozin combined with sitagliptincannotonly improve blood glucose in obese patients with type 2 diabetes mellitus，but also reduce visceral fat area and improve insulin resistance status.

[Keywords] Obese type2diabetesmelitus;Etogliflozin;Sitagliptin;Visceral fatarea

2型糖尿病（type2diabetesmellitus，T2DM）是胰岛素抵抗和β细胞功能减退导致的慢性代谢病，而肥胖尤其是以内脏脂肪异常蓄积为代表的中心性肥胖，是推动胰岛素抵抗形成和加重糖代谢紊乱的关键因素[。（剩余4164字）